|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
LIN, CHIH-HUI | WU, WEI- HSIU | Steve Pi | 02-77218877 | 3F., No.36, Ln. 358, Ruiguang Rd.,Neihu Dist., Taipei City 114, Taiwan | 2018/03/28 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Intech Biopharm Ltd, is a pharmaceutical company that develops, produces and markets specialized drugs focusing on the respiratory treatment categories. By owning strong RD team and the superior HFA MDI platforms with facilities at the high level as EMA and US FDA standard, we are not only supply high barrier generic drugs but also challenge 505b2 and new combination drug for obstructive airway diseases. In 2017, our new manufacturing site opened, which is a dedicated respiratory drug products manufacturing plant. This manufacturing site can offer 15 million MDI and 1.5million DPI products per year. Our mission is to provide Innovation, Quality, Professional and Care products and services to patients and customers. |
Market Information ( 2024/04/19 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
218.755 | 27.75 | 25.80 | 27.00 | -0.90 | 178 | .00 | 10 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/19) |
TPEx measures adopted (2024/04/19) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |